Abstract
Liposarcoma arising in the thoracic cavity is a rare entity. It is usually found in the retroperitoneal space and the extremities. No case of thoracic liposarcoma in a patient suffering from the end-stage renal disease has been reported in the literature. We herein present the first case of thoracic liposarcoma in a patient suffering from the end-stage renal disease. Metabolic disturbances, increased use of erythropoietin and increased diagnostic workup attributes to greater risk of cancer in patients suffering from renal failure. A chemotherapeutic drug, Trabectedin has been approved for advanced liposarcoma. Prognosis of such tumours depends on the size, location, and their histological subtype.
Original language | English (US) |
---|---|
Pages (from-to) | 286-289 |
Number of pages | 4 |
Journal | Journal of Ayub Medical College, Abbottabad : JAMC |
Volume | 31 |
Issue number | 2 |
State | Published - 2019 |
Keywords
- End-stage renal disease
- Erythropoietin
- Liposarcoma
- Thoracic cavity
- Trabectedin
ASJC Scopus subject areas
- Medicine(all)